| answer text |
<p>Research is crucial in tackling cancer, which is why the Department invests £1.3
billion per year in health research, through the National Institute for Health and
Care Research (NIHR). NIHR research expenditure for all cancers was £121.8 million
in 2022/23, and the NIHR spends more on cancer than any other disease group. <br>
<br> The NIHR funded nine research projects on pancreatic cancer since 2018/19, with
a committed funding value of £4.3 million. The NIHR continues to welcome funding applications
for research into any aspect of human health, including pancreatic cancer. Applications
are subject to peer review and judged in open competition. <br> <br> The NIHR also
supports delivery of research into pancreatic cancer in the health and care system,
funded by research funding partners in the charity and public sectors. Since 2018/19
the NIHR supported 73 clinical research studies through the Clinical Research Network.
<br> <br> Additionally, NIHR Biomedical Research Centres (BRC) and NIHR Clinical Research
Facilities spent a further £6.5 million between 2018/19 and 2022/23, supporting an
annual portfolio of approximately 85 early clinical studies into pancreatic cancer.
NIHR BRCs are collaborations between world-leading universities and National Health
Service organisations, that bring together academics and clinicians to translate discoveries
from basic or discovery science into clinical research. <br> <br> For emotional and
financial support, patient feedback is monitored through the National Cancer Patient
Experience Survey, with the latest results showing an overall experience of 8.88 out
of 10. In areas such as support for health and wellbeing, and information on financial
help, results were positive but showed room for improvement. NHS England continues
to support trusts to take action to improve cancer patient support.</p>
|
|
